Publications database

IDH-wildtype Glioblastoma (GB) is the most prevalent primary malignant CNS tumour in adults. The standard treatment regimen involves radiotherapy, which can cause radionecrotic (postactinic) changes as a late-onset treatment complication. [...]

Li-Fraumeni syndrome (LFS) is a rare autosomal dominant cancer predisposition syndrome characterized by a markedly elevated lifetime cancer risk. Despite the substantial psychological burden associated with LFS, tailored psychosocial interventions remain unavailable. [...]

Current liver T1 mapping methods present restricted liver coverage, take long acquisition times and mostly exclude the T1 bias induced by fat and iron effects. We evaluated the clinical feasibility of an accelerated water T1 (wT1) mapping method, including all liver segments and the potential of its T2*-compensation (wT1comp) for fibrosis tissue assessment.Forty-three patients were classified into three groups: benign without/with risk of developing fibrosis and hepatocellular carcinoma (HCC). [...]

Managing aggressive meningiomas remains challenging because of limited treatment options besides surgical tumor removal and radiotherapy. To increase the repertoire of promising therapies for aggressive meningiomas, we established a multistep drug screening workflow, focusing on targetable genes obtained from transcriptome data of highly aggressive grade 3 meningiomas. [...]

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, offering durable responses and prolonged survival. However, these therapies also present unique challenges, particularly with the onset of immune-related adverse events (irAEs), which can manifest during treatment either acutely and/or become chronic or emerge long after treatment cessation. [...]

Checkpoint inhibitor therapy with PD-1/PD-L1-antibodies has significant benefits in non-small-cell lung cancer treatment even in advanced stage IVA/B. While PD-L1 expression in tumor is a weak but relevant predictor of treatment response, impact and interaction of potential prognostic factors like ECOG status, LDH-levels, CRP-levels, and genetic mutations remain so far undefined. [...]